Lamotrigine
- Generic Name
- Lamotrigine
- Brand Names
- Lamictal
- Drug Type
- Small Molecule
- Chemical Formula
- C9H7Cl2N5
- CAS Number
- 84057-84-1
- Unique Ingredient Identifier
- U3H27498KS
- Background
Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 cou...
- Indication
Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.
...
- Associated Conditions
- Bipolar 1 Disorder, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Seizures, Generalized
- Associated Therapies
- Conversion to monotherapy
Acute Treatment of Bipolar II Depression
- First Posted Date
- 2003-12-22
- Last Posted Date
- 2012-07-23
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 102
- Registration Number
- NCT00074776
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States
Clinical Study Of Schizophrenia in Both Men and Women
- Conditions
- First Posted Date
- 2003-10-31
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 176
- Registration Number
- NCT00071747
- Locations
- 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States
Lamotrigine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-09-11
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 131
- Registration Number
- NCT00068445
- Locations
- 🇺🇸
Siouxland Hematology-Oncology Associates at June E. Nylen Cancer Center, Sioux City, Iowa, United States
🇺🇸Coborn Cancer Center, Saint Cloud, Minnesota, United States
🇺🇸Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
Bipolar Study in Adults at Least 18 Years of Age
- First Posted Date
- 2003-09-05
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1200
- Registration Number
- NCT00067938
- Locations
- 🇺🇸
GSK Investigational Site, West Allis, Wisconsin, United States
Combination Therapy for the Treatment of Bipolar Disorders
- Conditions
- Interventions
- First Posted Date
- 2003-06-27
- Last Posted Date
- 2016-11-06
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT00063362
Bipolar Disorder Study for Men and Women
- First Posted Date
- 2003-03-11
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00056277
- Locations
- 🇺🇸
GSK Investigational Site, Brown Deer, Wisconsin, United States
Pediatric Epilepsy Study in Subjects 1-24 Months
- Conditions
- First Posted Date
- 2002-08-26
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 197
- Registration Number
- NCT00044278
- Locations
- 🇹🇷
GSK Investigational Site, Ankara, Turkey
Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
- Conditions
- First Posted Date
- 2002-08-16
- Last Posted Date
- 2017-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT00043914
Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug
- Conditions
- First Posted Date
- 2002-08-16
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 141
- Registration Number
- NCT00043901
- Locations
- 🇵🇪
GSK Investigational Site, San Isidro, Lima, Peru
Pediatric Epilepsy Trial in Subjects 1-24 Months
- Conditions
- First Posted Date
- 2002-08-15
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 177
- Registration Number
- NCT00043875
- Locations
- 🇹🇷
GSK Investigational Site, Ankara, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.